MCE 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务。
CAS No. : 1358715-18-0
MCE 国际站:Fluzoparib
产品活性:Fluzoparib (SHR3162) 是一种有效的口服活性 PARP1 抑制剂(IC50=1.46±0.72 nM),具有优越的抗肿瘤活性。Fluzoparib 选择性地抑制同源重组修复 (HR) 缺陷细胞的增殖,并使 HR 缺陷细胞对细胞毒性活性分子敏感。Fluzoparib 在体内具有良好的药代动力学特性,可用于癌症研究。
研究领域:Cell Cycle/DNA Damage | Epigenetics
作用靶点:PARP
In Vitro: Fluzoparib (30?μM; 24 hour) increases the levels of γH2AX in a concentration‐dependent manner in both?BRCA2‐deficient V‐C8 cells and?BRCA1‐deficient MDA‐MB‐436 cells, but not in?BRCA‐proficient V‐C8#13‐5 cells.Fluzoparib (10?μM; 24 hour) increases levels of both pCDK1 and cyclin B, indicating activation of the G2/M checkpoint in MDA‐MB‐436 cells.Fluzoparib (10?μM; 72 hour) increases the processing of caspase‐3, ‐8, and ‐9 concentration‐dependently, it induces G2/M arrest and apoptosis in HR‐deficient?MDA‐MB‐436 cells?cells.Fluzoparib is preferentially efficacious against HR‐deficient cells, such as BRCA1‐deficient (UWB1.289), MDA‐MB‐436, BRCA2‐deficient (V‐C8), BRCA1‐deficientBRCA2‐mutated (MX‐1) and BRCA1?hypermethylated (OVCAR‐8) cells with IC50 values of 0.51?μM, 1.57?μM, 0.053?μM, 1.57?μM, and 1.43?μM, respectively. The IC50 values for HR‐proficient cells (V‐C8#13‐5 and UWB1.289 BRCA1) are both >10?μM.
In Vivo: Fluzoparib (oral gavage; 0.3, 1, or 3?mg/kg; single dose) exhibits a good pharmacokinetic profile in Female Balb/cA nude mice (5‐6 weeks old) mice bearing MDA‐MB‐436. After a single oral dose, fluzoparib is rapidly absorbed and rapidly cleared from blood at all dose levels; plasma concentrations of fluzoparib quickly reaches maximum within 2?hours. In contrast, concentrations of fluzoparib in tumor remains at high levels even at 24?hours after dosing (57.9?ng/g , 39.3 ng/g, and 85.6?ng/g for doses of 0.3, 1, and 3?mg/kg, respectively).Fluzoparib (oral gavage; 30 mg/kg; 21 days) apparently inhibits the growth of tumor with an inhibition rate of 59% (day 21) at 30?mg/kg, and it does not cause significant loss of body weight in Nude mice bearing?MDA‐MB‐436 ?(BRCA1‐deficient)?model.Fluzoparib (3mg/kg) combines with Cisplatin, Paclitaxel, or Apatinib (oral gavage; BID; 21 days) causes growth inhibition with rates of 61.4%, 55.3%, and 72.8%, respectively.Fluzoparib, Cisplatin, and Apatinib combination or Fluzoparib, Paclitaxel, and Apatinib combination can cause growth inhibition with rates of 84.9% and 75.6% (day 21), respectively in vivo.The 2‐drug combination of Fluzoparib with cisplatin and The 3‐drug Fluzoparib, Cisplatin, and Apatinib combination lead to loss of body weight, whereas no apparent toxicity was observed in other combinations.
相关产品:Drug Repurposing Compound Library Plus | FDA-Approved Drug Library Plus | FDA-Approved Drug Library Mini | Bioactive Compound Library Plus | Cell Cycle/DNA Damage Compound Library | Epigenetics Compound Library | FDA-Approved Drug Library | Anti-Cancer Compound Library | Anti-Aging Compound Library | Drug Repurposing Compound Library | NMPA-Approved Drug Library | FDA Approved & Pharmacopeial Drug Library | Anti-Breast Cancer Compound Library | Anti-Pancreatic Cancer Compound Library | FDA-Approved Anticancer Drug Library | Anti-Prostate Cancer Compound Library | Cancer Stem Cells Compound Library | Highly Selective Inhibitors Library | iRucaparib-AP6 | Rucaparib monocamsylate | AZD-2461 | RBN-2397 | Rucaparib acetate | Niraparib tosylate | Olaparib-d8 | G007-LK | Basroparib | Anticancer agent 64 | UPF 1069 | Talazoparib tosylate | BPA-B9 | MSC2504877 | Oxychlororaphine | PROTAC PARP1 degrader | 5,7-Dihydroxychromone | PARP1-IN-5 | OUL232 | Stenoparib | PI-1840 | PARP1-IN-11 | 3-Aminobenzamide | PARP1-IN-6 | OM-153 | BRCA1-IN-2 | PARP-2-IN-1 | JQAD1 | Dehydrocorydaline (hydroxyl)
热门产品线:重组蛋白 | 化合物库 | 天然产物 | 荧光染料 | PROTAC | 同位素标记物 | 寡核苷酸 | 抗体 | 点击化学
Trending products:Recombinant Proteins | Bioactive Screening Libraries | Natural Products | Fluorescent Dye | PROTAC | Isotope-Labeled Compounds | Oligonucleotides | Antibodies | Click Chemistry
货号: HY-114778
品牌介绍:
• MCE (MedChemExpress) 拥有200 多种全球独家化合物库,我们致力于为全球科研客户提供前沿最全的高品质小分子活性化合物;
• 50,000 多种高选择性抑制剂、激动剂涉及各热门信号通路及疾病领;
• 产品种类涵盖各种重组蛋白,多肽,常用试剂盒 ,更有 PROTAC、ADC 等特色产品,广泛应用于新药研发、生命科学等科研项目;
• 提供虚拟筛选,离子通道筛选,代谢组学分析检测分析,药物筛选等专业技术服务;
• 设有专业的实验中心和严格的质控、验证体系;
• 提供 LC/MS、NMR、HPLC、手性分析、元素分析等各项质检报告,确保产品的高纯度、高品质;
• 产品的生物活性多经各国客户实验验证;
• Nature, Cell, Science 等多种顶级期刊及制药专利收录了MCE客户的科研成果;
• 专业团队跟踪最新的制药及生命科学研究进展,为您提供全球最新的活性化合物;
• 与世界各大制药公司及知名科研机构建立了长期的合作。